Software provides an integrated technology platform for adaptive clinical trials
The new release combines ADDPLAN® BASE, ADDPLAN® MC (for Multiple Comparison Designs) and ADDPLAN® DF (for dose ranging and dose finding trials using MCP-Mod methodology) modules under one umbrella, increasing simulation speed for each application and allowing computation of multiple projects on one, integrated robust framework. The software has been rewritten using C programming language to ensure efficient usage of computing resources and fast simulation results.
Following feedback from customers, ICON enhanced the algorithms’ stability and speed and added new features such as the ability to incorporate custom R code in the ADDPLAN® neo Dose Finding module.
Additional ADDPLAN® neo features include:
- Every-Phase Capabilities – Strengthen and advance study design, simulation and analysis for every phase of drug development, including Adaptive MCP-Mod, critical for dose-finding designs.
- Improved User Experience – A fully validated, graphical user interface (GUI) software, ADDPLAN® neo features a quick access to adaptive approaches across all phases of drug development.
Further information is available at www.iconplc.com/addplanneo
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
ICON Media Contact
+44 (0)20 7067 0548